FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:937-940 August 30, 2007 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Psaty, B. M. Related Article by Nissen, S. E. PubMed Citation

To the Editor: The study by Nissen and Wolski (June 14 issue)¹ shows increased rates of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment for type 2 diabetes. The authors' results are intriguing because a simple calculation of the pooled data shows a higher rate of myocardial infarction in the control group than in the rosiglitazone group (0.59% vs. 0.55%). In contrast, the Peto odds ratio for myocardial infarction of 1.43 (95% confidence interval [CI], 1.03 to 1.98) that is reported in the article shows a significantly increased risk in the rosiglitazone group.

Since it is unusual . . . [Full Text of this Article]

This article has been cited by other articles:

• Dahabreh, I. J (2008). Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 5: 116-120 [Abstract]